Major adverse cardiovascular events

Major adverse cardiovascular events (MACE, or major adverse cardiac events) is a composite endpoint frequently used in cardiovascular research.[1][2] Despite widespread use of the term in clinical trials, the definitions of MACE can differ, which makes comparison of similar studies difficult.[3]

  1. ^ Bonora BM, Avogaro A, Fadini GP (2020). "Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 13: 161–174. doi:10.2147/DMSO.S233538. PMC 6982447. PMID 32021362.
  2. ^ Chong WH, Yanoff LB, Andraca-Carrera E, Hai MT (2020). "Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA". The New England Journal of Medicine. 383 (13): 1199–1202. doi:10.1056/NEJMp2004889. PMID 32966719. S2CID 221888300.
  3. ^ Kip KE, Hollabaugh K, Marroquin OC, Williams DO (2008). "The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention". Journal of the American College of Cardiology. 51 (7): 701–707. doi:10.1016/j.jacc.2007.10.034. PMID 18279733.